Related Experiment Video

Updated: May 26, 2026

Tissue Engineering: Construction of a Multicellular 3D Scaffold for the Delivery of Layered Cell Sheets
09:24

Tissue Engineering: Construction of a Multicellular 3D Scaffold for the Delivery of Layered Cell Sheets

Published on: October 3, 2014

Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM:

Yoshiki Sawa1, Shigeru Miyagawa, Taichi Sakaguchi

  • 1Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. sawa@surg1.med.osaka-u.ac.jp

Surgery Today
|December 28, 2011
PubMed

Insights

Cellular therapy using autologous myoblast sheets shows promise for treating dilated cardiomyopathy (DCM). This innovative treatment improved a patient's heart function, potentially offering an alternative to heart transplantation.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Biotechnology

Background:

  • Dilated cardiomyopathy (DCM) is a severe heart condition leading to heart failure and high mortality rates.
  • Cellular therapy is an emerging treatment strategy for end-stage heart failure.
  • Autologous myoblast sheets are being investigated for cardiac repair.

Observation:

  • A 56-year-old male patient with end-stage DCM received a transplant of autologous myoblast sheets.
  • The myoblast sheets were manufactured using temperature-responsive culture dishes.
  • The patient had previously relied on a left ventricular assist system.

Findings:

  • The patient experienced significant clinical improvement following the myoblast sheet transplant.
  • Arrhythmia resolved completely, and the patient was able to discontinue the left ventricular assist system.
  • The treatment successfully avoided the need for cardiac transplantation.

Implications:

  • Cellular therapy with myoblast sheets represents a promising new therapeutic approach for end-stage DCM.
  • This regenerative medicine strategy may offer an effective alternative to heart transplantation in the future.
  • Further research into myoblast sheet therapy could advance treatment options for heart failure patients.

More Related Videos

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

Engineered Vascularized Muscle Flap08:18

Engineered Vascularized Muscle Flap

Published on: January 11, 2016

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...